Kenneth R Chapman

List of Publications by Year
in descending order

154 papers	9,318 citations	47006 47 h-index	39675 94 g-index
154 all docs	154 docs citations	154 times ranked	7689 citing authors

#	Article	IF	Citations
1	Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respiratory Medicine,the, 2022, 10, 11-25.	10.7	109
2	If All That You Have Is a Hammerâ€¦: Can We Phenotype Our Patients with Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 266-267.	5.6	0
3	Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1391-1402.	5.6	19
4	Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 44-55.	5.6	24
5	Primary Care Severe Asthma Registry and Education Project (PCSAR-EDU): Phase 1 â€“ an e-Delphi for registry definitions and indices of clinician behaviour. BMJ Open, 2022, 12, e055958.	1.9	0
6	Association of Obstructive Apnea with Thoracic Fluid Shift and Small Airways Narrowing in Asthma During Sleep. Nature and Science of Sleep, 2022, Volume 14, 891-899.	2.7	2
7	Chronic Obstructive Pulmonary Disease: Is Social Injustice the Elephant in the Room?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1331-1332.	5.6	1
8	Dyspnoea and symptom burden in mildâ€“moderate COPD: the Canadian Cohort Obstructive Lung Disease Study. ERJ Open Research, 2021, 7, 00960-2020.	2.6	7
9	The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study. International Journal of COPD, 2021, Volume 16, 305-320.	2.3	16
10	The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. International Journal of COPD, 2021, Volume 16, 689-699.	2.3	0
11	Î±1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action. Lancet Respiratory Medicine,the, 2021, 9, 337-339.	10.7	46
12	Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma. Clinical Drug Investigation, 2021, 41, 489-492.	2.2	1
13	Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respiratory Research, 2021, 22, 144.	3.6	18
14	Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. Expert Review of Respiratory Medicine, 2021, 15, 1093-1106.	2.5	3
15	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. International Journal of COPD, 2021, Volume 16, 1755-1770.	2.3	30
16	Dysanapsis and the Spirometric Response to Inhaled Bronchodilators. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 997-1001.	5.6	4
17	One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies. BMJ Open Respiratory Research, 2021, 8, e000819.	3.0	4
18	Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Advances in Therapy, 2021, 38, 5381-5397.	2.9	0

#	Article	IF	Citations
19	Just as the Twig Is Bent, the Treeâ€™s Inclined. Annals of the American Thoracic Society, 2021, 18, 1461-1463.	3.2	0
20	Asthma patients' and physiciansâ€™ perspectives on the burden and management of asthma. Respiratory Medicine, 2021, 186, 106524.	2.9	21
21	Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Respiratory Research, 2021, 22, 272.	3.6	1
22	Trust but Verify. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4288-4289.	3.8	1
23	Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. Chest, 2020, 158, 2270-2274.	0.8	12
24	Bench to Bedside and Back: The Evolving Story of Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 403-404.	2.9	3
25	Once-daily, single-inhaler mometasoneâ€“indacterolâ€“glycopyrronium versus mometasoneâ€“indacterol or twice-daily fluticasoneâ€“salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respiratory Medicine,the, 2020, 8, 1000-1012.	10.7	98
26	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 214-225.	0.5	3
27	Anticholinergic Bronchodilator Therapy of Asthmaâ€”Ageless. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2661-2662.	3.8	0
28	Addressing Reduced Laboratory-Based Pulmonary Function Testing During a Pandemic. Chest, 2020, 158, 2502-2510.	0.8	63
29	Targeted management of severe asthma: Developing a Canadian approach. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 124-132.	0.5	1
30	Identification and definition of asthmaâ€“COPD overlap: The CanCOLD study. Respirology, 2020, 25, 836-849.	2.3	45
31	Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. BioImpacts, 2020, 10, 209-215.	1.5	98
32	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 43-51.	5.6	6
33	Impaired Sleep Quality in COPD Is Associated With Exacerbations. Chest, 2019, 156, 852-863.	0.8	47
34	The effects of marijuana smoking on lung function in older people. European Respiratory Journal, 2019, 54, 1900826.	6.7	32
35	The Hidden Story of Nonadherence with Asthma Therapy: For a Few Dollars More?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2307-2308.	3.8	2
36	Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study . International Journal of COPD, 2019, Volume 14, 249-260.	2.3	12

#	Article	IF	Citations
37	Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661985072.	2.6	4
38	Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2019, 321, 1693.	7.4	25
39	The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1716-1726.	5.7	106
40	Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Pulmonary Therapy, 2019, 5, 23-41.	2.2	7
41	Efficacy and safety of inhaled Î±1-antitrypsin in patients with severe Î±1-antitrypsin deficiency and frequent exacerbations of COPD. European Respiratory Journal, 2019, 54, 1900673.	6.7	55
42	Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study. Respiratory Medicine, 2019, 146, 1-9.	2.9	22
43	Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 390-392.	5.6	1
44	Health Services Burden of Undiagnosed and Overdiagnosed COPD. Chest, 2018, 153, 1336-1346.	0.8	60
45	Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1223-1226.	5.6	25
46	Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 968-969.	5.6	0
47	Improving Asthma Management: A Tale of Two Countries. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1926.	3.8	0
48	Safety of biweekly Î±₁-antitrypsin treatment in the RAPID programme. European Respiratory Journal, 2018, 52, 1800897.	6.7	10
49	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 329-339.	5.6	196
50	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. International Journal of COPD, 2018, Volume 13, 1125-1134.	2.3	14
51	Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. International Journal of COPD, 2018, Volume 13, 419-432.	2.3	37
52	Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 5-15.	0.7	7
53	A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study. Journal of Glaucoma, 2017, 26, 182-186.	1.6	17
54	Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1189-1197.	5.6	139

#	Article	IF	Citations
55	Long-term efficacy and safety of Î±1 proteinase inhibitor treatment for emphysema caused by severe Î±1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respiratory Medicine,the, 2017, 5, 51-60.	10.7	151
56	Work productivity loss in mild to moderate COPD: lessons learned from the CanCOLD study. European Respiratory Journal, 2017, 50, 1701154.	6.7	9
57	Quantitative disease progression model of Î±â€1 proteinase inhibitor therapy on computed tomography lung density in patients with Î±â€1 antitrypsin deficiency. British Journal of Clinical Pharmacology, 2017, 83, 2386-2397.	2.4	9
58	Asthma biomarkers in the age of biologics. Allergy, Asthma and Clinical Immunology, 2017, 13, 48.	2.0	68
59	Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1230-1231.	5.6	2
60	Improving the Management of COPD inÂWomen. Chest, 2017, 151, 686-696.	0.8	86
61	Physician perspectives on the burden and management of asthma in six countries: The Global Asthma Physician Survey (GAPS). BMC Pulmonary Medicine, 2017, 17, 153.	2.0	52
62	The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 34-44.	0.7	42
63	Self-Management and Clinical Decision Support for Patients With Complex Chronic Conditions Through the Use of Smartphone-Based Telemonitoring: Randomized Controlled Trial Protocol. JMIR Research Protocols, 2017, 6, e229.	1.0	16
64	Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study. , 2017, , .		0
65	Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study. , 2017, , .		0
66	Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study. , 2017, , .		0
67	Safety of bi-weekly intravenous therapy with alpha-1 antitrypsin. , 2017, , .		1
68	Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1. , 2017, , .		1
69	The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. International Journal of COPD, 2016, Volume 11, 2041-2053.	2.3	20
70	The Arietta Study: Exploring Severe Asthma Biomarkers in a Real-World Setting. Journal of Allergy and Clinical Immunology, 2016, 137, AB256.	2.9	1
71	Current thinking and new paradigm for COPD. Respiratory Medicine, 2016, 112, 126-127.	2.9	1
72	Indacaterolâ€“Glycopyrronium versus Salmeterolâ€“Fluticasone for COPD. New England Journal of Medicine, 2016, 374, 2222-2234.	27.0	688

#	Article	IF	Citations
73	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine,the, 2016, 4, 781-796.	10.7	398
74	The relationship between omega-3 and smoking habit: a cross-sectional study. Lipids in Health and Disease, 2016, 15, 61.	3.0	26
75	Factors associated with undiagnosed and overdiagnosed COPD. European Respiratory Journal, 2016, 48, 561-564.	6.7	33
76	Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respiratory Medicine, 2016, 115, 7-12.	2.9	16
77	The COPD Assessment Test. Chest, 2016, 150, 1069-1079.	0.8	11
78	Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 285-298.	5.6	110
79	Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study. , 2016, , .		1
80	Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. PLoS ONE, 2016, 11, e0166745.	2.5	63
81	Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies. Chronic Obstructive Pulmonary Diseases (Miami,) Tj ETQq1 1 0.784314 rgBT /Ove		4
82	Increased proportion of slow decliners in patients with alpha-1 protease inhibitor (A1-PI) deficiency following treatment with A1-PI. , 2016, , .		1
83	Correlation between change in lung density and lung function parameters in treated alpha-1 protease inhibitor (A1-PI) deficiency. , 2016, , .		0
84	Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease. Respirology, 2015, 20, 987-993.	2.3	9
85	Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and) Tj ETQq1 1 0.784314 rgBT /Overlo		82
86	Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. International Journal of COPD, 2015, 10, 1599.	2.3	19
87	The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, hasÂplateaued. Respiratory Medicine, 2015, 109, 308-311.	2.9	3
88	Intravenous augmentation treatment and lung density in severe Î±1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 386, 360-368.	13.7	408
89	Alpha-1 Antitrypsin Deficiency in Canada: Regional Disparities in Diagnosis and Management. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 15-21.	1.6	16
90	Exacerbations in non-COPD patients: truth or mythâ€"authorsâ€™ response. Thorax, 2014, 69, 1050.2-1051.	5.6	0

#	Article	IF	Citations
91	Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 125-132.	1.6	122
92	Minimal Clinically Important Differences in Pharmacological Trials. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 250-255.	5.6	360
93	A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulmonary Medicine, 2014, 14, 4.	2.0	70
94	Quality Assurance of Spirometry in a Population-Based Study â€“Predictors of Good Outcome in Spirometry Testing. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 143-151.	1.6	23
95	QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 48-60.	0.7	7
96	Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study. Respiratory Medicine, 2013, 107, 1558-1567.	2.9	82
97	Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respiratory Medicine,the, 2013, 1, 524-533.	10.7	219
98	Do We Know the Minimal Clinically Important Difference (MCID) for COPD Exacerbations?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 243-249.	1.6	29
99	Bronchodilator Responsiveness and Reported Respiratory Symptoms in an Adult Population. PLoS ONE, 2013, 8, e58932.	2.5	14
100	Randomised controlled trial for emphysema with a selective agonist of the Î³-type retinoic acid receptor. European Respiratory Journal, 2012, 40, 306-312.	6.7	77
101	Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease: Figure 1:. Cmaj, 2012, 184, 1365-1371.	2.0	72
102	A Step Forward in COPD Management. Chest, 2012, 142, 1082-1085.	0.8	0
103	Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. International Journal of COPD, 2012, 7, 145.	2.3	10
104	The clinical impact of single inhaler therapy in asthma. Clinical and Experimental Allergy, 2012, 42, 1006-1013.	2.9	7
105	Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. International Journal of COPD, 2011, 6, 353.	2.3	76
106	Mortality among Subjects with Chronic Obstructive Pulmonary Disease or Asthma at Two Respiratory Disease Clinics in Ontario. Canadian Respiratory Journal, 2011, 18, 327-332.	1.6	5
107	Long-term Safety and Efficacy of Indacaterol, a Long-Acting Î²2-Agonist, in Subjects With COPD. Chest, 2011, 140, 68-75.	0.8	126
108	Pharmacokinetic comparability of ProlastinÂ®-C to ProlastinÂ® in alpha1-antitrypsin deficiency: a randomized study. BMC Clinical Pharmacology, 2010, 10, 13.	2.5	35

#	Article	IF	Citations
109	Asthma that is unresponsive to usual care. Cmaj, 2010, 182, 45-52.	2.0	5
110	Dynamic Airway Evaluation with Volume CT: Initial Experience. Canadian Association of Radiologists Journal, 2010, 61, 90-97.	2.0	24
111	SMART isn't. Journal of Allergy and Clinical Immunology, 2010, 125, 609-610.	2.9	4
112	Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax, 2010, 65, 747-752.	5.6	69
113	Letter to the Editor Response. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010, 7, 235-236.	1.6	1
114	Are Women More Susceptible to Chronic Obstructive Pulmonary Disease?. , 2010, , 252-259.		0
115	Omalizumab for asthma: pharmacology and clinical profile. Expert Review of Respiratory Medicine, 2009, 3, 119-127.	2.5	7
116	Augmentation Therapy for Î±₁Antitrypsin Deficiency: A Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 177-184.	1.6	160
117	A Cohort Study of Traffic-Related Air Pollution and Mortality in Toronto, Ontario, Canada. Environmental Health Perspectives, 2009, 117, 772-777.	6.0	190
118	Suboptimal asthma control: prevalence, detection and consequences in general practice. European Respiratory Journal, 2008, 31, 320-325.	6.7	293
119	Safer Inhaled Corticosteroid Therapy for Asthma. Pediatrics, 2008, 121, 179-180.	2.1	5
120	Asthma in Canada: missing the treatment targets. Cmaj, 2008, 178, 1027-1028.	2.0	5
121	Tiotropium in Combination with Placebo, Salmeterol, or Fluticasoneâ€“Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine, 2007, 146, 545.	3.9	590
122	Tiotropium and Simplified Detection of Dynamic Hyperinflation. Chest, 2007, 131, 690-695.	0.8	18
123	Women and Asthma: Lessons from a Gender Analysis of the Asthma in Canada Survey. Journal of Asthma, 2006, 43, 169-173.	1.7	11
124	Epidemiology and costs of chronic obstructive pulmonary disease. European Respiratory Journal, 2006, 27, 188-207.	6.7	606
125	Asthma Control in Canada Remains Suboptimal: The Reality of Asthma Control (TRAC) Study. Canadian Respiratory Journal, 2006, 13, 253-259.	1.6	187
126	Le RÃ1e de lâ€™Omalizumab dans le Traitement de lâ€™Asthme Allergique Grave. Canadian Respiratory Journal, 2006, 13, 10B-20B.	1.6	0

#	Article	IF	Citations
127	The Role of Omalizumab in the Treatment of Severe Allergic Asthma. Canadian Respiratory Journal, 2006, 13, 1B-9B.	1.6	16
128	Adult Asthma Consensus Guidelines Update 2003. Canadian Respiratory Journal, 2004, 11, 9A-18A.	1.6	171
129	Evaluation of a Questionnaire to Assess Compliance with Antiâ€asthma Medications. Journal of Asthma, 2004, 41, 77-83.	1.7	19
130	Chronic obstructive pulmonary disease: are women more susceptible than men?. Clinics in Chest Medicine, 2004, 25, 331-341.	2.1	96
131	The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults. Clinical Therapeutics, 2003, 25, C2-C14.	2.5	9
132	Economic Issues in the Use of Office Spirometry for Lung Health Assessment. Canadian Respiratory Journal, 2003, 10, 320-326.	1.6	10
133	Relation between income, air pollution and mortality: a cohort study. Cmaj, 2003, 169, 397-402.	2.0	48
134	Seretide for obstructive lung disease. Expert Opinion on Pharmacotherapy, 2002, 3, 341-350.	1.8	11
135	The Addition of Salmeterol 50 Âµg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial. Canadian Respiratory Journal, 2002, 9, 178-185.	1.6	51
136	Control of Asthma in Canada: Failure to Achieve Guideline Targets. Canadian Respiratory Journal, 2001, 8, 35A-40A.	1.6	124
137	Patient Handling of a Dry-Powder Inhaler in Clinical Practice. Chest, 2001, 120, 1480-1484.	0.8	31
138	Gender Bias in the Diagnosis of COPD. Chest, 2001, 119, 1691-1695.	0.8	319
139	Difficult Asthma: Consider All of the Possibilities. Canadian Respiratory Journal, 2000, 7, 415-418.	1.6	5
140	Reality-Based Medicine. Chest, 2000, 118, 281-283.	0.8	10
141	The Placebo Effect in Asthma Drug Therapy Trials: A Meta-Analysis. Journal of Asthma, 2000, 37, 303-318.	1.7	54
142	Inhaler Education for Hospital-Based Pharmacists: How Much Is Required?. Canadian Respiratory Journal, 1999, 6, 237-244.	1.6	23
143	Effect of Inhaled Furosemide in Acute Asthma. Journal of Asthma, 1998, 35, 89-93.	1.7	24
144	The Patient Level Cost of Asthma in Adults in South Central Ontario. Canadian Respiratory Journal, 1998, 5, 463-471.	1.6	30

#	Article	IF	Citations
145	Prehospitalization Inhaled Corticosteroid Use in Patients With COPD or Asthma. Chest, 1997, 111, 296-302.	0.8	40
146	The Effect of Structured Versus Conventional Inhaler Education in Medical Housestaff. Journal of Asthma, 1996, 33, 385-393.	1.7	34
147	Adverse effects of inhaled corticosteroids. American Journal of Medicine, 1995, 98, 196-208.	1.5	239
148	Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 1995, 96, 571-579.	2.9	163
149	The Choice of Inhalers in Adults and Children over Six. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 1995, 8, S-27-S-36.	1.2	6
150	Asthma Education: The United Kingdom Experience. Chest, 1994, 106, 216S-218S.	0.8	12
151	Physician Perceptions and Management of COPD. Chest, 1993, 104, 254-258.	0.8	126
152	Tracheobronchial dilation during isocapnic hypoxia in conscious humans. Journal of Applied Physiology, 1993, 75, 1728-1733.	2.5	13
153	Effect of a Short Course of Prednisone in the Prevention of Early Relapse after the Emergency Room Treatment of Acute Asthma. New England Journal of Medicine, 1991, 324, 788-794.	27.0	193
154	Maximal Inspiratory and Expiratory Pressures in Adolescents. Chest, 1984, 86, 568-572.	0.8	107